Evidence map›Paper›PMID 18982019›Full record

ArticleImmunology and cell biology2009

MHC class II-expressing thymocytes suppress invariant NKT cell development.

Wei Li, M Hanief Sofi, Datsen G Wei, Wenjun Du, Jacquelyn Gervay-Hague, Gourapura J Renukaradhya, Randy R Brutkiewicz, Cheong-Hee Chang

Open access · bronzeAbstract read
In one paragraph

Article in Immunology and cell biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2014
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Wei LiDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA.
M Hanief Sofi
Datsen G Wei
Wenjun Du
Jacquelyn Gervay-Hague
Gourapura J Renukaradhya
Randy R Brutkiewicz
Cheong-Hee Chang
Indiana University School of MedicineUniversity of California, Davis · USUniversity of Michigan–Ann Arbor · USIndiana University – Purdue University Indianapolis · USUniversity of Chicago · US

Funding

Synthesis and Screening of Bioactive GlycolipidsR01GM090262 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GERVAY-HAGUE, JACQUELYN · 2009 to 2012
$1.2M
Immune regulation by thymocyte-selected CD4 T cellsR56AI073677 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHANG, CHEONG-HEE · 2008 to 2008
$357k
NIAID NIH HHS AI66642NIAID NIH HHS R56 AI073677NIGMS NIH HHS R01 GM090262
6 · The paper itself

Abstract

Natural killer T (NKT) cells are positively selected on cortical thymocytes expressing the non-classical major histocompatibility complex (MHC) class I CD1d molecules. However, it is less clear how NKT cells are negatively selected in the thymus. In this study, we investigated the role of MHC class II expression in NKT cell development. Transgenic mice expressing MHC class II on thymocytes and peripheral T cells had a marked reduction in invariant NKT (iNKT) cells. Reduced numbers of iNKT cells correlated with the absence of in vivo production of cytokines in response to the iNKT cell agonist alpha-galactosylceramide. Using mixed bone marrow chimeras, we found that MHC class II-expressing thymocytes suppressed the development of iNKT cells in trans in a CD4-dependent manner. Our observations have significant implications for human iNKT cell development as human thymocytes express MHC class II, which can lead to an inefficient selection of iNKT cells.

Indexed as

AnimalsCell DifferentiationFlow CytometryHistocompatibility Antigens Class IIHumansMiceMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicNatural Killer T-CellsNuclear ProteinsThymus GlandTrans-ActivatorsHistocompatibility Antigens Class IIMHC class II transactivator proteinNuclear ProteinsTrans-Activators

Identifiers

PMID18982019
PMCPMC2801351
OpenAlexW2050487940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.